Company: LHI
Filing Date: 2025-02-14
Form Type: DRS/A
Source: 0001213900-25-014190
Chunk: 228

Company: Living Homeopathy International Ltd.
Filing Date: 2025-02-14
Form: DRS/A
Chunk 228
---
>

We agreed to reimburse the Representative for
reasonable out-of-pocket accountable expenses of no more than US$250,000, regardless of whether this Offering is closed.

We advanced an expense deposit of US$70,000 to
the Representative after the execution of the letter of intent between us and the Representative, US$80,000 at the first public filing
of this registration statement and US$100,000 upon the effectiveness of this registration statement for the Representative’s anticipated
out-of-pocket expenses. In the event the IPO is terminated or is not successfully closed, any unused portion of the advanced payment will
be returned to us to the extent not actually incurred in accordance with FINRA Rule 5110(g)(4)(A).

We also agreed to pay to the Representative non-accountable expenses
equal to 1.0% of the gross proceeds raised in this Offering.

We estimate that the total expenses payable by us in connection with this Offering, other than the underwriting fees, commissions and the Representative’s accountable expense and non-accountable expense, will be approximately US$[●].

Lock-Up Agreements

We agreed that, subject to certain exceptions
set forth in the underwriting agreement/lock-up agreements, we will not, without the prior written consent of the Representative, from
the date of execution of the underwriting agreement and continuing for six (6) months from the date of this Offering, (i) offer,
sell, or otherwise transfer or dispose of, directly or indirectly, any Class A Ordinary Shares of the Company or any securities convertible
into or exercisable or exchangeable for Class A Ordinary Shares of the Company; or (ii) file or caused to be filed any registration statement
with the SEC relating to the offering of any Class A Ordinary Shares of the Company or any securities convertible into or exercisable
or exchangeable for Class A Ordinary Shares of the Company.

Each of our officers, directors, and all existing
shareholders who own 5% or more of the issued and outstanding Class A Ordinary Shares after this Offering agree not to offer, issue, sell,
contract to sell, encumber, grant any option for the sale of or otherwise dispose of any Class A Ordinary Shares or other securities convertible
into or exercisable or exchangeable for Class A Ordinary Shares for up to six (6) months from the closing of this Offering, without
the prior written consent of the Representative.

The Representative may in its sole discretion
and at any time without notice release some or all of the shares subject to